RecruitingPhase 1Phase 2NCT04459065
Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery
Sponsor
University of Saskatchewan
Enrollment
36 participants
Start Date
Sep 1, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria11
- Surgically resectable Stage I and II non-small cell lung cancer
- Able to give informed consent
- Age ≥ 18 and ≤ 80 years old
- Adequate cardiopulmonary reserve to undergo lung resection as determined by operating surgeon
- No prior history of malignancy
- No neoadjuvant therapy
- Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2
- Hemoglobin (hgb) ≥ 90 g/L
- White blood cell count (WBC) \> 3 x 109/L
- Platelet count (plt) ≥ 100 x 109/L
- Serum creatinine ≤ 1.5 times upper reference range
Exclusion Criteria7
- Received anti-EGFR antibody therapy (cetuximab, panitumumab, necitumumab) within 60 days prior to trial drug
- Pregnant or nursing
- Known history of hypersensitivities or allergic reactions to antibodies or NSO derived products
- Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
- Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
- Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
- Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug
Interventions
DRUGIRDye800CW-nimotuzumab
50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04459065
Related Trials
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
NCT062954971 location
Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block
NCT066185991 location
Rhomboid Intercostal Block vs Erector Spinae Block
NCT070406181 location